Targeting Major Cancer Markets

Edison Oncology was founded in 2018 by experienced life science industry veterans to develop and commercialize new therapies targeting the fight against cancer.

About Edison Oncology

Identifying and Advancing Underdeveloped Candidates

By leveraging our deep understanding of tumor biology and translational drug development expertise, we seek to identify and acquire select underdeveloped drug candidates, and specifically target them to patients whose tumors are most likely to respond to therapy.

View Our Approach

Developing Disruptive Drug Candidates

We are developing a pipeline of unique small-molecule product candidates, each with several “shots on goal” in both orphan and major cancer markets. Our goal is address unmet medical needs and improve the lives of cancer patients whose tumors harbor mutations known to be targeted by our product candidates.

Learn More about our product development pipeline

Email Alerts

Stay informed and receive company updates straight to your inbox.

Sign me up for company announcements: